Cargando…
Midbiotics: conjugative plasmids for genetic engineering of natural gut flora
The possibility to modify gut bacterial flora has become an important goal, and various approaches are used to achieve desirable communities. However, the genetic engineering of existing microbes in the gut, which are already compatible with the rest of the community and host immune system, has not...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6866695/ https://www.ncbi.nlm.nih.gov/pubmed/30951393 http://dx.doi.org/10.1080/19490976.2019.1591136 |
_version_ | 1783472094177132544 |
---|---|
author | Ruotsalainen, Pilvi Penttinen, Reetta Mattila, Sari Jalasvuori, Matti |
author_facet | Ruotsalainen, Pilvi Penttinen, Reetta Mattila, Sari Jalasvuori, Matti |
author_sort | Ruotsalainen, Pilvi |
collection | PubMed |
description | The possibility to modify gut bacterial flora has become an important goal, and various approaches are used to achieve desirable communities. However, the genetic engineering of existing microbes in the gut, which are already compatible with the rest of the community and host immune system, has not received much attention. Here, we discuss and experimentally evaluate the possibility to use modified and mobilizable CRISPR-Cas9-endocing plasmid as a tool to induce changes in bacterial communities. This plasmid system (briefly midbiotic) is delivered from bacterial vector into target bacteria via conjugation. Compared to, for example, bacteriophage-based applications, the benefits of conjugative plasmids include their independence of any particular receptor(s) on host bacteria and their relative immunity to bacterial defense mechanisms (such as restriction-modification systems) due to the synthesis of the complementary strand with host-specific epigenetic modifications. We show that conjugative plasmid in association with a mobilizable antibiotic resistance gene targeting CRISPR-plasmid efficiently causes ESBL-positive transconjugants to lose their resistance, and multiple gene types can be targeted simultaneously by introducing several CRISPR RNA encoding segments into the transferred plasmids. In the rare cases where the midbiotic plasmids failed to resensitize bacteria to antibiotics, the CRISPR spacer(s) and their adjacent repeats or larger regions were found to be lost. Results also revealed potential caveats in the design of conjugative engineering systems as well as workarounds to minimize these risks. |
format | Online Article Text |
id | pubmed-6866695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-68666952019-12-03 Midbiotics: conjugative plasmids for genetic engineering of natural gut flora Ruotsalainen, Pilvi Penttinen, Reetta Mattila, Sari Jalasvuori, Matti Gut Microbes Brief Report The possibility to modify gut bacterial flora has become an important goal, and various approaches are used to achieve desirable communities. However, the genetic engineering of existing microbes in the gut, which are already compatible with the rest of the community and host immune system, has not received much attention. Here, we discuss and experimentally evaluate the possibility to use modified and mobilizable CRISPR-Cas9-endocing plasmid as a tool to induce changes in bacterial communities. This plasmid system (briefly midbiotic) is delivered from bacterial vector into target bacteria via conjugation. Compared to, for example, bacteriophage-based applications, the benefits of conjugative plasmids include their independence of any particular receptor(s) on host bacteria and their relative immunity to bacterial defense mechanisms (such as restriction-modification systems) due to the synthesis of the complementary strand with host-specific epigenetic modifications. We show that conjugative plasmid in association with a mobilizable antibiotic resistance gene targeting CRISPR-plasmid efficiently causes ESBL-positive transconjugants to lose their resistance, and multiple gene types can be targeted simultaneously by introducing several CRISPR RNA encoding segments into the transferred plasmids. In the rare cases where the midbiotic plasmids failed to resensitize bacteria to antibiotics, the CRISPR spacer(s) and their adjacent repeats or larger regions were found to be lost. Results also revealed potential caveats in the design of conjugative engineering systems as well as workarounds to minimize these risks. Taylor & Francis 2019-04-05 /pmc/articles/PMC6866695/ /pubmed/30951393 http://dx.doi.org/10.1080/19490976.2019.1591136 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Brief Report Ruotsalainen, Pilvi Penttinen, Reetta Mattila, Sari Jalasvuori, Matti Midbiotics: conjugative plasmids for genetic engineering of natural gut flora |
title | Midbiotics: conjugative plasmids for genetic engineering of natural gut flora |
title_full | Midbiotics: conjugative plasmids for genetic engineering of natural gut flora |
title_fullStr | Midbiotics: conjugative plasmids for genetic engineering of natural gut flora |
title_full_unstemmed | Midbiotics: conjugative plasmids for genetic engineering of natural gut flora |
title_short | Midbiotics: conjugative plasmids for genetic engineering of natural gut flora |
title_sort | midbiotics: conjugative plasmids for genetic engineering of natural gut flora |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6866695/ https://www.ncbi.nlm.nih.gov/pubmed/30951393 http://dx.doi.org/10.1080/19490976.2019.1591136 |
work_keys_str_mv | AT ruotsalainenpilvi midbioticsconjugativeplasmidsforgeneticengineeringofnaturalgutflora AT penttinenreetta midbioticsconjugativeplasmidsforgeneticengineeringofnaturalgutflora AT mattilasari midbioticsconjugativeplasmidsforgeneticengineeringofnaturalgutflora AT jalasvuorimatti midbioticsconjugativeplasmidsforgeneticengineeringofnaturalgutflora |